Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Companies warn investors that DOGE’s federal cuts might hurt business
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
pharmaphorum20h
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney disease
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
pharmaphorum20h
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Novo Nordisk has asked the FDA to stop compounding pharmacies making ... The request follows a similar move by Eli Lilly, which has asked for a ban on other parties making copies of its ...